top of page
Group 371.png

Events

We’ll be taking Dzuveo on the road in 2023, aiming to meet as many of you as possible. Come and say hello to the Aguettant team, we’re going to be at the following events… 

hummingbird.png

Munich

24th-27th May

European Society of Anaesthesiology and Intensive Care - Euroanaesthesia

Harrogate

25th-27th September

Association of Anaesthetists Annual Congress

Bristol

7th June

Association of Dental Anaesthetists and Seditionists Annual Conference (ADAS)

London

26th-27th September

British Association of Aesthetic Plastic Surgeons (BAAPS)

Cardiff

20th-21st June

British Association of Day Surgery (BADS) Annual Conference

London

1st-2nd October

Future Surgery

Warwick

19th-20th September

The National Acute Pain Symposium 2024 (NAPS)

Gateshead

8th-10th October

Royal College of Emergency Medicine Annual Scientific Conference (RCEM)

Analgesia, designed for your healthcare environment

Post operative
pain

Patients who mobilise sooner recover quicker (1). Dzuveo® supports you to gain control over patient comfort, so they can follow what's needed for their recovery.

Emergency &
trauma pain

In an emergency, relieving pain is an urgent priority. Dzuveo® takes effect quickly to make your patients comfortable, so you can work on their other clinical needs.

Procedural
pain

If a patient experiences pain during their procedure, whether it be a dressing change, burn debridement or an endoscopy, it could affect their overall outcome and clinical experience. Dzuveo®'s efficient analgesia supports you in getting patient pain under control.

Group 371a.png

Dzuveo® allows you to control your patient's pain urgently and non-invasively, prioritising patient care and comfort.

Request an
appointment to
see a Key
Account Manager

To find out more about how our Dzuveo® sublingual sufentanil 30 mcg tablet can support you in providing excellent patient care, request an appointment now.

Simply fill in the form, and an Aguettant team member will arrange a date and time to suit you.

Thanks for submitting!

Safety information

Dzuveo is to be administered by a healthcare professional in a medically monitored setting only. A medically monitored setting must have equipment and personnel trained to detect and manage hypoventilation, and availability of supplemental oxygen and opioid antagonists, such as naloxone. Dzuveo should only be prescribed and administered by healthcare professionals who are experienced in the management of opioid therapy; particularly opioid adverse reactions, such as respiratory depression

References 1. Twomey R, Matthews TW, Nakoneshny S, Schrag C, Chandarana SP, Matthews J, McKenzie D, Hart RD, Li N, Sauro KM, Dort JC. Impact of Early Mobilization on Recovery after Major Head and Neck Surgery with Free Flap Reconstruction. Cancers (Basel). 2021 Jun 8;13(12):2852. doi: 10.3390/cancers13122852. PMID: 34201003; PMCID: PMC8227616.

bottom of page